Assessment and Management of Nocturnal Paranoia and Agitation in Dementia

1. Systematic Assessment of Modifiable Contributors

Before any antipsychotic is considered, the American Psychiatric Association recommends a structured evaluation of reversible factors that can trigger nocturnal paranoia and agitation in persons with dementia [1][2].
Pain should be screened with a validated dementia‑appropriate tool because unrecognized pain frequently precipitates behavioral disturbances 1.
Screen for acute infections (e.g., urinary tract infection, pneumonia) as they are common precipitants of sudden behavioral change in older adults residing in care facilities 1.
Review the environment for inadequate lighting, excessive noise, uncomfortable temperature, or lack of perceived safety during nighttime 1.
Document the patient’s sleep‑wake pattern to identify circadian rhythm disruptions that may underlie nocturnal symptoms 1.

The APA mandates that structured daily activities and exercise (≈ 50–60 minutes of physical activity distributed throughout the day) be implemented, as they have been shown to reduce agitation and improve sleep in dementia 3.
Enhancing social engagement—regular daytime family contact and group interactions—mitigates loneliness‑related paranoia and lowers nocturnal anxiety 3.

Antipsychotics should be initiated only when nocturnal paranoia or agitation is severe, poses safety risks, or causes significant distress after exhaustive non‑pharmacological measures have been applied [1][2].

Evidence indicates that antipsychotic therapy in dementia is associated with an increased risk of mortality 4.
Clinical trials demonstrate modest efficacy, with benefits described as “at best small” 4.
In patients with vascular or mixed dementia, antipsychotics carry an elevated stroke risk 4.

For mixed/vascular dementia with psychosis and agitation, risperidone or quetiapine are the preferred agents [1][2].
Begin at the lowest possible dose (risperidone 0.25 mg or quetiapine 12.5–25 mg at bedtime) and titrate slowly to the minimum effective dose [1][2].
Reassess after 4 weeks; if there is no clinically meaningful improvement, taper and discontinue the medication [1][2].
Even with a positive response, regularly evaluate the need for continuation and plan for eventual discontinuation [1][2].

Do not add antipsychotics reflexively without first addressing reversible causes and trialing non‑pharmacologic strategies [1][2].
Recognize that sertraline at higher doses may contribute to agitation and paranoid ideation; consider switching to a better‑tolerated SSRI (e.g., citalopram or escitalopram) before adding other agents 1.
Fluoxetine should be avoided in older adults due to its long half‑life and heightened side‑effect profile 3.
Anticholinergic antidepressants (tricyclics) are contraindicated because they worsen cognition in dementia 3.

Employ a quantitative instrument (e.g., Cohen‑Mansfield Agitation Inventory or Neuropsychiatric Inventory) to track treatment response [1][2].
Record the frequency and severity of nocturnal calls and paranoid accusations as objective outcome metrics 3.
Conduct weekly assessments initially, transitioning to monthly reviews once the patient’s condition stabilizes 3.